“With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a ...
Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...
If 2025 had a theme for the Charlotte region's life sciences ecosystem, it was this: years of planning finally meeting their moment. From landmark facility openings to record-breaking workforce ...
Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the appointment of Maykin Ho, Ph.D., to its board of directors, and the promotions of Nathan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results